Insulet Corporation which can be found using ticker (PODD) have now 18 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $270.00 and $208.00 and has a mean target at $238.13. Now with the previous closing price of $164.00 and the analysts are correct then we can expect a percentage increase in value of 45.2%. The 50 day MA is $197.52 and the 200 day moving average is $211.46. The market cap for the company is 11.83B. The stock price for the company is currently $169.25 USD
The potential market cap would be $17,184,454,023 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 57.57, revenue per share of $24.33 and a 6.09% return on assets.
Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta.
